Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duligotuzumab - Genentech

Drug Profile

Duligotuzumab - Genentech

Alternative Names: Anti-HER3/EGFR DAF; MEHD-7945A; RG 7597; RO-5541078

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; Roche
  • Developer Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Colorectal cancer; Head and neck cancer

Most Recent Events

  • 04 Jun 2018 Genentech terminates a phase I trial for Solid tumours (Combination therapy, Late stage disease, Metastatic disease) in USA and Spain (NCT01986166)
  • 23 Apr 2018 Genentech completes a phase I trial for Solid tumours in USA and Spain (NCT01207323)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Spain (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top